pms-IRBESARTAN Recall: Affected Lot May Contain Wrong Tablets

Source: Health Canada · Canada

Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.

Pharmascience Inc. is recalling one lot of pms-IRBESARTAN 150 mg tablets because it may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets instead.

What this Health Canada recall tells you, and what most readers miss

This notice was issued by Health Canada on August 12, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, health-product.

What Happened

The affected lot of pms-IRBESARTAN may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets.

Which Products Are Affected

  • Brand: Pharmascience Inc.
  • Product Name: pms-IRBESARTAN
  • DIN: 02317079
  • Dosage Form: Tablet
  • Strength: 150 mg
  • Lot Number: 667278

Depth of recall: Retailers. The recall was published on 2026-08-12.

What You Should Do

Verify whether your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.

Why This Matters

The mix-up involves a prescription medication, which may affect proper treatment for patients.

Source

Health Canada

Original source: Health Canada Official Notice ↗

All Product & Food Recalls →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Frequently Asked Questions

Common questions about this Health Canada recall.

What is this Health Canada recall about?
Pharmascience Inc. is recalling one lot of pms-IRBESARTAN 150 mg tablets because it may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets instead.
Which agency issued this alert?
This alert was issued by Health Canada. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects Canada. Check with Health Canada for the most current geographic scope.
Where can I find more Product & Food Recalls updates?
Browse the full Product & Food Recalls feed on Areazine at areazine.com/ca/recalls/ for the latest updates from Health Canada and other agencies.